Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 63

1.

Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases.

van Burik JA, Hare RS, Solomon HF, Corrado ML, Kontoyiannis DP.

Clin Infect Dis. 2006 Apr 1;42(7):e61-5. Epub 2006 Feb 21. Erratum in: Clin Infect Dis. 2006 Nov 15;43(10):1376.

PMID:
16511748
2.

Hydroxylated analogues of the orally active broad spectrum antifungal, Sch 51048 (1), and the discovery of posaconazole [Sch 56592; 2 or (S,S)-5].

Bennett F, Saksena AK, Lovey RG, Liu YT, Patel NM, Pinto P, Pike R, Jao E, Girijavallabhan VM, Ganguly AK, Loebenberg D, Wang H, Cacciapuoti A, Moss E, Menzel F, Hare RS, Nomeir A.

Bioorg Med Chem Lett. 2006 Jan 1;16(1):186-90. Epub 2005 Nov 2.

PMID:
16260134
3.

Activity of posaconazole in the treatment of central nervous system fungal infections.

Pitisuttithum P, Negroni R, Graybill JR, Bustamante B, Pappas P, Chapman S, Hare RS, Hardalo CJ.

J Antimicrob Chemother. 2005 Oct;56(4):745-55. Epub 2005 Aug 31.

PMID:
16135526
4.

Posaconazole is a potent inhibitor of sterol 14alpha-demethylation in yeasts and molds.

Munayyer HK, Mann PA, Chau AS, Yarosh-Tomaine T, Greene JR, Hare RS, Heimark L, Palermo RE, Loebenberg D, McNicholas PM.

Antimicrob Agents Chemother. 2004 Oct;48(10):3690-6.

5.

Changes in susceptibility to posaconazole in clinical isolates of Candida albicans.

Li X, Brown N, Chau AS, López-Ribot JL, Ruesga MT, Quindos G, Mendrick CA, Hare RS, Loebenberg D, DiDomenico B, McNicholas PM.

J Antimicrob Chemother. 2004 Jan;53(1):74-80. Epub 2003 Dec 4.

PMID:
14657086
6.

Mutations in Aspergillus fumigatus resulting in reduced susceptibility to posaconazole appear to be restricted to a single amino acid in the cytochrome P450 14alpha-demethylase.

Mann PA, Parmegiani RM, Wei SQ, Mendrick CA, Li X, Loebenberg D, DiDomenico B, Hare RS, Walker SS, McNicholas PM.

Antimicrob Agents Chemother. 2003 Feb;47(2):577-81.

7.

The use of direct cDNA selection to rapidly and effectively identify genes in the fungus Aspergillus fumigatus.

Kessler MM, Willins DA, Zeng Q, Del Mastro RG, Cook R, Doucette-Stamm L, Lee H, Caron A, McClanahan TK, Wang L, Greene J, Hare RS, Cottarel G, Shimer GH Jr.

Fungal Genet Biol. 2002 Jun;36(1):59-70.

PMID:
12051895
8.

EmtA, a rRNA methyltransferase conferring high-level evernimicin resistance.

Mann PA, Xiong L, Mankin AS, Chau AS, Mendrick CA, Najarian DJ, Cramer CA, Loebenberg D, Coates E, Murgolo NJ, Aarestrup FM, Goering RV, Black TA, Hare RS, McNicholas PM.

Mol Microbiol. 2001 Sep;41(6):1349-56.

9.

Genetic footprinting in bacteria.

Hare RS, Walker SS, Dorman TE, Greene JR, Guzman LM, Kenney TJ, Sulavik MC, Baradaran K, Houseweart C, Yu H, Foldes Z, Motzer A, Walbridge M, Shimer GH Jr, Shaw KJ.

J Bacteriol. 2001 Mar;183(5):1694-706.

10.

In vitro Gram-positive antimicrobial activity of evernimicin (SCH 27899), a novel oligosaccharide, compared with other antimicrobials: a multicentre international trial.

Jones RN, Hare RS, Sabatelli FJ; Ziracin Susceptibility Testing Group.

J Antimicrob Chemother. 2001 Jan;47(1):15-25.

PMID:
11152427
11.

Effects of mutations in ribosomal protein L16 on susceptibility and accumulation of evernimicin.

McNicholas PM, Mann PA, Najarian DJ, Miesel L, Hare RS, Black TA.

Antimicrob Agents Chemother. 2001 Jan;45(1):79-83.

12.

Evernimicin (SCH27899) inhibits a novel ribosome target site: analysis of 23S ribosomal DNA mutants.

Adrian PV, Mendrick C, Loebenberg D, McNicholas P, Shaw KJ, Klugman KP, Hare RS, Black TA.

Antimicrob Agents Chemother. 2000 Nov;44(11):3101-6.

13.

In vitro and in vivo activities of SCH 56592 (posaconazole), a new triazole antifungal agent, against Aspergillus and Candida.

Cacciapuoti A, Loebenberg D, Corcoran E, Menzel F Jr, Moss EL Jr, Norris C, Michalski M, Raynor K, Halpern J, Mendrick C, Arnold B, Antonacci B, Parmegiani R, Yarosh-Tomaine T, Miller GH, Hare RS.

Antimicrob Agents Chemother. 2000 Aug;44(8):2017-22.

14.

Efficacy of SCH27899 in an animal model of Legionnaires' disease using immunocompromised A/J mice.

Brieland JK, Loebenberg D, Menzel F, Hare RS.

Antimicrob Agents Chemother. 2000 May;44(5):1333-6.

15.

Evernimicin binds exclusively to the 50S ribosomal subunit and inhibits translation in cell-free systems derived from both gram-positive and gram-negative bacteria.

McNicholas PM, Najarian DJ, Mann PA, Hesk D, Hare RS, Shaw KJ, Black TA.

Antimicrob Agents Chemother. 2000 May;44(5):1121-6.

16.

Mutations in ribosomal protein L16 conferring reduced susceptibility to evernimicin (SCH27899): implications for mechanism of action.

Adrian PV, Zhao W, Black TA, Shaw KJ, Hare RS, Klugman KP.

Antimicrob Agents Chemother. 2000 Mar;44(3):732-8.

17.

Genomics and antimicrobial drug discovery.

Moir DT, Shaw KJ, Hare RS, Vovis GF.

Antimicrob Agents Chemother. 1999 Mar;43(3):439-46. Review. No abstract available.

18.

Synthesis and antibacterial activity of 2-alkoxy penems.

Afonso A, Hon F, Fett N, Weinstein J, Ganguly AK, Naples L, Hare RS, Miller GH.

Bioorg Med Chem Lett. 1998 Oct 6;8(19):2793-6.

PMID:
9873624
19.

The application of molecular techniques for the study of aminoglycoside resistance.

Shaw KJ, Sabatelli FJ, Naples L, Mann P, Hare RS, Miller GH.

Methods Mol Med. 1998;15:555-77. doi: 10.1385/0-89603-498-4:555.

PMID:
21390766
20.
21.

The most frequent aminoglycoside resistance mechanisms--changes with time and geographic area: a reflection of aminoglycoside usage patterns? Aminoglycoside Resistance Study Groups.

Miller GH, Sabatelli FJ, Hare RS, Glupczynski Y, Mackey P, Shlaes D, Shimizu K, Shaw KJ.

Clin Infect Dis. 1997 Jan;24 Suppl 1:S46-62.

PMID:
8994779
22.

Cloning and characterization of a 3-N-aminoglycoside acetyltransferase gene, aac(3)-Ib, from Pseudomonas aeruginosa.

Schwocho LR, Schaffner CP, Miller GH, Hare RS, Shaw KJ.

Antimicrob Agents Chemother. 1995 Aug;39(8):1790-6.

23.
24.

Cloning and characterization of KNR4, a yeast gene involved in (1,3)-beta-glucan synthesis.

Hong Z, Mann P, Brown NH, Tran LE, Shaw KJ, Hare RS, DiDomenico B.

Mol Cell Biol. 1994 Feb;14(2):1017-25.

25.

Analysis of the aac(3)-VIa gene encoding a novel 3-N-acetyltransferase.

Rather PN, Mann PA, Mierzwa R, Hare RS, Miller GH, Shaw KJ.

Antimicrob Agents Chemother. 1993 Oct;37(10):2074-9.

26.

Nucleotide sequence analysis and DNA hybridization studies of the ant(4')-IIa gene from Pseudomonas aeruginosa.

Shaw KJ, Munayyer H, Rather PN, Hare RS, Miller GH.

Antimicrob Agents Chemother. 1993 Apr;37(4):708-14.

27.
28.

Determination of aminoglycoside resistance mechanisms of Enterobacteriaceae isolated from a hospital in Hong Kong with antibiogram and genotyping.

Ho BS, Hare RS, Shaw KJ, Miller GH, Ng MH.

J Antimicrob Chemother. 1993 Jan;31(1):174-6. No abstract available.

PMID:
8444663
29.

Sch 39304, a new antifungal agent: oral and topical treatment of vaginal and superficial infections.

Parmegiani RM, Loebenberg D, Cacciapuoti A, Antonacci B, Norris C, Menzel F, Moss L, Yarosh-Tomaine T, Hare RS, Miller GH.

J Med Vet Mycol. 1993;31(3):239-48.

PMID:
8360815
30.

Cloning and DNA sequence analysis of an aac(3)-Vb gene from Serratia marcescens.

Rather PN, Mierzwa R, Hare RS, Miller GH, Shaw KJ.

Antimicrob Agents Chemother. 1992 Oct;36(10):2222-7.

31.

Abrupt onset of weakness and seizure in a 39-year-old woman.

Evans TC, Van Hare RS.

Ann Emerg Med. 1992 Sep;21(9):1145-52. No abstract available.

PMID:
1514732
32.

Characterization of the chromosomal aac(6')-Ic gene from Serratia marcescens.

Shaw KJ, Rather PN, Sabatelli FJ, Mann P, Munayyer H, Mierzwa R, Petrikkos GL, Hare RS, Miller GH, Bennett P, Downey P.

Antimicrob Agents Chemother. 1992 Jul;36(7):1447-55.

33.

The ring of C2 and evaluation of the cross-table lateral view of the cervical spine.

Van Hare RS, Yaron M.

Ann Emerg Med. 1992 Jun;21(6):733-5. Review.

PMID:
1590618
35.

Revision of standards for adjusting the cation content of Mueller-Hinton broth for testing susceptibility of Pseudomonas aeruginosa to aminoglycosides.

Barry AL, Reller LB, Miller GH, Washington JA, Schoenknect FD, Peterson LR, Hare RS, Knapp C.

J Clin Microbiol. 1992 Mar;30(3):585-9.

36.

In vitro and in vivo activities of SCH 42427, the active enantiomer of the antifungal agent SCH 39304.

Loebenberg D, Cacciapuoti A, Parmegiani R, Moss EL Jr, Menzel F Jr, Antonacci B, Norris C, Yarosh-Tomaine T, Hare RS, Miller GH.

Antimicrob Agents Chemother. 1992 Feb;36(2):498-501.

37.

Comparison of SCH 39304, fluconazole, and ketoconazole for treatment of systemic infections in mice.

Cacciapuoti A, Loebenberg D, Parmegiani R, Antonacci B, Norris C, Moss EL Jr, Menzel F Jr, Yarosh-Tomaine T, Hare RS, Miller GH.

Antimicrob Agents Chemother. 1992 Jan;36(1):64-7.

38.

Correlation between aminoglycoside resistance profiles and DNA hybridization of clinical isolates.

Shaw KJ, Hare RS, Sabatelli FJ, Rizzo M, Cramer CA, Naples L, Kocsi S, Munayyer H, Mann P, Miller GH, et al.

Antimicrob Agents Chemother. 1991 Nov;35(11):2253-61.

39.

Appearance of amikacin and tobramycin resistance due to 4'-aminoglycoside nucleotidyltransferase [ANT(4')-II] in gram-negative pathogens.

Jacoby GA, Blaser MJ, Santanam P, Hächler H, Kayser FH, Hare RS, Miller GH.

Antimicrob Agents Chemother. 1990 Dec;34(12):2381-6.

40.

Microbiological and pharmacokinetic studies of acyl demycinosyltylosin and related tylosin derivatives.

Cacciapuoti AF, Loebenberg D, Moss EL Jr, Menzel FW, Rudeen JA, Naples LR, Cramer CL, Hare RS, Mallams AK, Miller GH.

J Antibiot (Tokyo). 1990 Sep;43(9):1131-6.

42.

Isolation, characterization, and DNA sequence analysis of an AAC(6')-II gene from Pseudomonas aeruginosa.

Shaw KJ, Cramer CA, Rizzo M, Mierzwa R, Gewain K, Miller GH, Hare RS.

Antimicrob Agents Chemother. 1989 Dec;33(12):2052-62.

44.

In vitro and in vivo characterization of novel 8-methoxy derivatives of chlortetracycline.

Cacciapuoti A, Moss EL Jr, Menzel F Jr, Cramer CA, Weiss W, Loebenberg D, Hare RS, Miller GH.

J Antibiot (Tokyo). 1987 Oct;40(10):1426-30.

45.

Influence of cation supplements on activity of netilmicin against Pseudomonas aeruginosa in vitro and in vivo.

Barry AL, Miller GH, Thornsberry C, Hare RS, Jones RN, Lorber RR, Ferraresi R, Cramer C.

Antimicrob Agents Chemother. 1987 Oct;31(10):1514-8.

46.

"Mbotay, pasi wapi?" ("Hello, where does it hurt?").

Van Hare RS.

Tex Med. 1987 Sep;83(9 Pt 1):84-5. No abstract available.

PMID:
3672398
47.

Netilmicin disk susceptibility tests: effect of cations on the MIC correlates.

Barry AL, Miller GH, Hare RS, Thornsberry C, Jones RN.

Eur J Clin Microbiol. 1987 Aug;6(4):416-7.

PMID:
3117533
48.

Effect of NaCl supplementation of Mueller-Hinton broth on susceptibility of staphylococci to aminoglycosides.

Campos JM, Gill CJ, Hare RS, Miller GH.

Antimicrob Agents Chemother. 1986 Jan;29(1):152-4.

49.

Comparison of aminoglycoside resistance patterns in Japan, Formosa, and Korea, Chile, and the United States.

Shimizu K, Kumada T, Hsieh WC, Chung HY, Chong Y, Hare RS, Miller GH, Sabatelli FJ, Howard J.

Antimicrob Agents Chemother. 1985 Aug;28(2):282-8.

50.

In-vitro activity of Sch 34343 against Gram-negative bacteria producing characterized beta-lactamases.

Dornbusch K, Frolander F, Cacciapuoti AF, Naples L, Hare RS, Miller GH.

J Antimicrob Chemother. 1985 Jun;15 Suppl C:85-97.

PMID:
3897175

Supplemental Content

Support Center